Catalyst Pharmaceuticals, Inc. - Common Stock (NQ:CPRX)

31.49 UNCHANGED

Last Price Updated: 4:00 PM EDT, Jul 14, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Catalyst Pharmaceuticals, Inc. - Common Stock

< Previous 1 2

...

8 9 10 11 12 13 14 15 Next >

Amylyx Pharmaceuticals Stock Sees Relative Strength Rating Rise To 98 ↗

September 09, 2022

Amylyx Pharmaceuticals stock hit a key technical milestone, seeing its Relative Strength Rating improve to 98, up from 83 the day before.

Via Investor's Business Daily

Agios Pharmaceuticals Stock Clears Key Benchmark, Hitting 90-Plus RS Rating ↗

September 02, 2022

Agios Pharmaceuticals stock saw a welcome improvement to its Relative Strength (RS) Rating on Friday, with an increase from 65 to 93.

Via Investor's Business Daily

Legend Biotech Stock Joins Elite Club Of Stocks With RS Ratings Over 90 ↗

September 01, 2022

On Thursday, Legend Biotech stock had its Relative Strength (RS) Rating upgraded to 91, up from 87 a day earlier.

Via Investor's Business Daily

Intercept Pharmaceutical Stock Shows Market Leadership; Earns 92 RS Rating ↗

August 30, 2022

On Tuesday, Intercept Pharmaceutical stock had its Relative Strength Rating upgraded to 92, up from 89 a day earlier.

Via Investor's Business Daily

15 Biotech Stocks That Hit Year Highs Over The Last Week, Including Sarepta, Axsome ↗

August 30, 2022

Not all shares are slowing down alongside the industry group.

Via Investor's Business Daily

Piper Sandler Increases Catalyst Pharma's Price Target Slightly After Q4 Earnings ↗

March 17, 2022

Via Benzinga

Relay Therapeutics Stock Shows Market Leadership With Jump To 94 RS Rating ↗

August 25, 2022

Relay Therapeutics stock saw a positive improvement to its Relative Strength (RS) Rating on Thursday, with an upgrade from 84 to 94.

Via Investor's Business Daily

Benzinga's Top Ratings Upgrades, Downgrades For August 24, 2022 ↗

August 24, 2022

Via Benzinga

Kymera Therapeutics Stock Scores Rising Relative Price Strength ↗

August 22, 2022

Kymera Therapeutics stock hit a key performance benchmark, with its Relative Strength Rating upgradedjulie mak to 94.

Via Investor's Business Daily

Rocket Pharmaceuticals Stock Scores Rising Relative Strength Upgrade ↗

August 11, 2022

On Thursday, Rocket Pharmaceuticals stock received an upgrade to its Relative Strength (RS) Rating, from 88 to 94.

Via Investor's Business Daily

11 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

August 10, 2022

Gainers

Via Benzinga

Catalyst Pharmaceuticals: Q2 Earnings Insights ↗

August 09, 2022

Catalyst Pharmaceuticals (NASDAQ:CPRX) reported its Q2 earnings results on Tuesday, August 9, 2022 at 04:00 PM. Here's what investors need to know about the announcement.

Via Benzinga

Why Catalyst Pharmaceuticals Shares Are Moving Today ↗

August 09, 2022

Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) shares are trading lower by 1.47% at $10.71. Traders and investors are watching for the company’s second-quarter earnings report, confirmed for Tuesday’s...

Via Benzinga

Kura Oncology Stock Joins Rank Of Stocks With RS Ratings Over 90 ↗

August 08, 2022

On Monday, Kura Oncology stock had its Relative Strength (RS) Rating upgraded to 91, up from 85 a day earlier.

Via Investor's Business Daily

A Preview Of Catalyst Pharmaceuticals' Earnings ↗

August 08, 2022

Catalyst Pharmaceuticals (NASDAQ:CPRX) is set to give its latest quarterly earnings report on Tuesday, 2022-08-09. Here's what investors need to know before the announcement.

Via Benzinga

Catalyst Pharmaceuticals to Report Second Quarter 2022 Financial Results on August 9, 2022

July 26, 2022

The Company Will Host a Conference Call and Webcast on August 10, 2022, at 8:30 AM ET

From Catalyst Pharmaceuticals, Inc.

Via GlobeNewswire

The Daily Biotech Pulse: GSK To Supply 50M Flu Vaccine Doses To US, FDA Lifts Hold On Greenwich's Cancer Immunotherapy Trial, Connect Biopharma Sees CBP-201 Topline Data Sooner ↗

July 12, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves ↗

May 10, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

6 Best-Performing Robinhood Stocks Of 2022 ↗

May 06, 2022

The SPDR S&P 500 ETF Trust (NYSE: SPY) is off to a brutal start to 2022, down 12.1% year-to-date. Robinhood Markets Inc (NASDAQ: HOOD) has been one of the worst performers of all so far this year,...

Via Benzinga

7 Smart Stocks to Buy Now Under $10 ↗

April 05, 2022

There are always good stocks to buy somewhere. What you should be focused on is finding the smart stocks that add value to your portfolio.

Via InvestorPlace

This Coal Company's 1-Year Return Handily Beats Moderna, Catalyst Pharmaceuticals, Globalstar And Dogecoin ↗

March 26, 2022

Alpha Metallurgical Resources Inc (NYSE:AMR) is known as a le...

Via Benzinga

Catalyst Pharmaceuticals's Return On Capital Employed Insights ↗

March 17, 2022

According to Benzinga Pro data Catalyst Pharmaceuticals (NASDAQ:CPRX) posted a 9.88% decrease in earnings from Q3. Sales, however, increased by 6.55% over the previous quarter to...

Via Benzinga

Recap: Catalyst Pharmaceuticals Q4 Earnings ↗

March 16, 2022

Catalyst Pharmaceuticals (NASDAQ:CPRX) reported its Q4 earnings results on Wednesday, March 16, 2022 at 04:00 PM. Here's what investors need to know about the announcement....

Via Benzinga

The Daily Biotech Pulse: Pfizer-BioNTech Apply For Authorization Of 3rd Booster Shot, Sanofi-Seagen Strike Cancer Therapy Pact, Iovance Gets Nod For Cancer Study ↗

March 16, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

Earnings Scheduled For March 16, 2022 ↗

March 16, 2022

Companies Reporting Before The Bell • Ideanomics (NASDAQ:IDEX) is likely to report quarterly loss at $0.05 per share on revenue of $33.20 million. • Tarena...

Via Benzinga

Earnings Preview For Catalyst Pharmaceuticals ↗

March 15, 2022

Catalyst Pharmaceuticals (NASDAQ:CPRX) is set to give its latest quarterly earnings report on Wednesday, 2022-03-16. Here's what investors need to know before the announcement....

Via Benzinga

Catalyst Pharma Expects FY22 Revenue Beat Consensus On Continued Recovery In Macroeconomic, Healthcare Activity ↗

February 07, 2022

Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) anticipates

Via Benzinga

The Week Ahead In Biotech (March 13-19): Bristol-Myers Squibb's Melanoma Drug Decision, Multiple Conference Presentations And Earnings Dominate Proceedings ↗

March 13, 2022

Biotech stocks pulled back for a second week running, as the Ukraine war cast its cloud on the broader market. Dwindling earnings news flow and company-specific developments...

Via Benzinga

7 of the Top-Rated Pharmaceutical Stocks for Q1 ↗

January 18, 2022

As the market begins to shift from high-growth, tech-fueled start-ups, one good long-term growth option is quality pharmaceutical stocks.

Via InvestorPlace

47 Biggest Movers From Yesterday ↗

February 08, 2022

Gainers Nuvectis Pharma, Inc. (NASDAQ: NVCT) shares surged 144.6% to close at $7.95 on Monday. The company, on Friday, priced its IPO at $5 per share. Anghami Inc. (NASDAQ: ANGH...

Via Benzinga

< Previous 1 2

...

8 9 10 11 12 13 14 15 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.